School of Medicine


Showing 1-48 of 48 Results

  • Leah Backhus

    Leah Backhus

    Thelma and Henry Doelger Professor of Cardiovascular Surgery

    BioLeah Backhus trained in general surgery at the University of Southern California and cardiothoracic surgery at the University of California Los Angeles. She practices at Stanford Hospital and is Chief of Thoracic Surgery at the VA Palo Alto. Her surgical practice consists of general thoracic surgery with special emphasis on thoracic oncology and minimally invasive surgical techniques. She is also Co-Director of the Thoracic Surgery Clinical Research Program, and has grant funding through the Veterans Affairs Administration and NIH. Her current research interests are in imaging surveillance following treatment for lung cancer and cancer survivorship. She is a member of the National Lung Cancer Roundtable of the American Cancer Society and the Task Group on Health Equity. She also serves on the Board of Directors of the Society of Thoracic Surgeons. As an educator, Dr. Backhus is the Associate Program Director for the Thoracic Track Residency and is former Chair of the ACGME Residency Review Committee for Thoracic Surgery.

  • Annelise E. Barron

    Annelise E. Barron

    Associate Professor of Bioengineering
    On Leave from 04/01/2024 To 06/30/2024

    Current Research and Scholarly InterestsBiophysical mechanisms of host defense peptides (a.k.a. antimicrobial peptides) and their peptoid mimics; also, molecular and cellular biophysics of human innate immune responses.

  • Michael Bassik

    Michael Bassik

    Associate Professor of Genetics

    Current Research and Scholarly InterestsWe are an interdisciplinary lab focused on two major areas:(1) we seek to understand mechanisms of cancer growth and drug resistance in order to find new therapeutic targets(2) we study mechanisms by which macrophages and other cells take up diverse materials by endocytosis and phagocytosis; these substrates range from bacteria, viruses, and cancer cells to drugs and protein toxins. To accomplish these goals, we develop and use new technologies for high-throughput functional genomics.

  • Philip Beachy

    Philip Beachy

    The Ernest and Amelia Gallo Professor, Professor of Urology, of Developmental Biology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsFunction of Hedgehog proteins and other extracellular signals in morphogenesis (pattern formation), in injury repair and regeneration (pattern maintenance). We study how the distribution of such signals is regulated in tissues, how cells perceive and respond to distinct concentrations of signals, and how such signaling pathways arose in evolution. We also study the normal roles of such signals in stem-cell physiology and their abnormal roles in the formation and expansion of cancer stem cells.

  • Christopher Beaulieu M.D., Ph.D.

    Christopher Beaulieu M.D., Ph.D.

    Professor of Radiology (Musculoskeletal Imaging)

    Current Research and Scholarly InterestsInformatics and image processing techniques that provide infrastructure for diagnosis in musculoskeletal imaging. Decision support for improving accuracy of bone tumor diagnosis. Improved methods for MRI in the musculoskeletal system.

  • Hans-Christoph Becker, MD, FSABI, FSCCT

    Hans-Christoph Becker, MD, FSABI, FSCCT

    Clinical Professor, Radiology

    Current Research and Scholarly InterestsMyocardial bridges (MB) with associated upfront atherosclerotic lesions are common findings on coronary computed tomography angiography (CTA). Abnormal septal wall motion in exercise echocardiography (EE) may to be associated with MB. Intravascular ultrasound (IVUS) is considered the gold standard for the detection of MB. We investigate whether CTA is comparable to IVUS for the assessment of MB and upstream plaques in symptomatic patients with suspicion for MB raised by EE.

  • Harmeet Bedi

    Harmeet Bedi

    Clinical Associate Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine

    BioDr. Harmeet Bedi is the Director of Interventional Pulmonology & Bronchoscopy at Stanford University. His expertise is in minimally invasive techniques used in the diagnosis and treatment of various airway and lung diseases such as lung cancer, benign & malignant airway obstruction, and pleural diseases. He specializes in rigid & flexible bronchoscopy, robotic bronchoscopy, airway stent placement, balloon bronchoplasty, endobronchial ultrasound (EBUS), and various pleural procedures. He also specializes in a variety of tumor ablative therapies including laser therapy, electrocautery, argon plasma coagulation (APC), brachytherapy, and cryotherapy.

    He founded the cone-beam computed tomography (CBCT) - guided bronchoscopy program at Stanford in 2019. CBCT-guided bronchoscopy is a novel and cutting-edge technique which combines bronchoscopy with CT imaging, allowing for improved localization and diagnosis of peripheral lung nodules. Additionally, CBCT-guided bronchoscopy will allow for numerous potential cancer therapies that are currently under development.

    Dr. Bedi is a principal investigator and co-investigator on multiple clinical trials related to bronchoscopy, thoracic imaging, pulmonary nodules, and lung cancer. Specifically, he has multiple research interests within the realm of bronchoscopic device innovation and CBCT-guided bronchoscopy.

  • Corinne Beinat

    Corinne Beinat

    Assistant Professor of Radiology (Molecular Imaging Program at Stanford)

    Current Research and Scholarly InterestsThe focus of my research is to develop novel imaging and treatment strategies to detect and better manage cancer. This approach relies first on the identification and validation of molecular targets and biomarkers that are linked with underlying the underlying biology driving the initiation and progression of cancers. We then develop novel small molecule based radiotracers to monitor fundamental molecular and cellular processes occurring in living subjects using positron emission tomography (PET) with the goal of improving cancer diagnosis and management. We additionally develop novel peptide based theragnostic agents for stratification of patients with high receptor expression, treatment with targeted radionuclide therapy, and subsequent monitoring of treatment response. Our overall goal is to develop multiple clinically translatable strategies to improve cancer diagnosis, management, and outcomes.

  • Gill Bejerano

    Gill Bejerano

    Professor of Developmental Biology, of Computer Science, of Pediatrics (Genetics) and of Biomedical Data Science

    Current Research and Scholarly Interests1. Automating monogenic patient diagnosis.
    2. The genomic signatures of independent divergent and convergent trait evolution in mammals.
    3. The logic of human gene regulation.
    4. The reasons for sequence ultraconservation.
    5. Cryptogenomics to bridge medical silos.
    6. Cryptogenetics to debate social injustice.
    7. Managing patient risk using machine learning.
    8. Understanding the flow of money in the US healthcare system.

  • Sean Bendall

    Sean Bendall

    Associate Professor of Pathology

    Current Research and Scholarly InterestsOur goal is to understand the mechanisms regulating the development of human systems. Drawing on both pluripotent stem cell biology, hematopoiesis, and immunology, combined with novel high-content single-cell analysis (CyTOF – Mass Cytometry) and imagining (MIBI-Multiplexed Ion Beam Imaging) we are creating templates of ‘normal’ human cellular behavior to both discover novel regulatory events and cell populations as well as understand dysfunctional processes such as cancer.

  • Catherine Benedict

    Catherine Benedict

    Clinical Associate Professor, Psychiatry and Behavioral Sciences - Medical Psychiatry

    Current Research and Scholarly InterestsMy research focuses on improving cancer survivorship through better understanding of long-term health outcomes and through the development of theoretically driven, evidence-based behavioral interventions to improve adjustment, risk management, and quality of life. To this end, I lead studies aimed to guide and support patient decision-making and self-management after cancer. Much of my work focuses on the experiences of young adults affected by cancer.

  • Jonathan S. Berek, MD, MMSc

    Jonathan S. Berek, MD, MMSc

    Laurie Kraus Lacob Professor

    BioLaurie Kraus Lacob Professor
    Stanford University School of Medicine

    Director, Stanford Women’s Cancer Center
    Senior Advisor, Stanford Cancer Institute

    Executive Director, Stanford Health Communication Initiative
    Director, MedArts Films
    Stanford Center for Health Education
    Stanford University

  • Dominique Bergmann

    Dominique Bergmann

    Shirley R. and Leonard W. Ely, Jr. Professor of the School of Humanities and Sciences

    Current Research and Scholarly InterestsWe use genetic, genomic and cell biological approaches to study cell fate acquisition, focusing on cases where cell fate is correlated with asymmetric cell division.

  • Daniel Bernstein

    Daniel Bernstein

    Alfred Woodley Salter and Mabel G. Salter Endowed Professor of Pediatrics

    Current Research and Scholarly Interests1. Using iPSC-derived cardiomyocytes to understand hypertrophic cardiomyopathy and heart failure associated with congenital heart disease.
    2. Role of alterations in mitochondrial dycamics and function in normal physiology and disease.
    3. Differences between R and L ventricular responses to stress,
    4. Immune biomarkers of risk after pediatric VAD implantation.
    5. Biomarkers for post-transplant lymphoproliferative disorder.

  • Alice Bertaina MD, PhD

    Alice Bertaina MD, PhD

    Lorry I. Lokey Professor

    Current Research and Scholarly InterestsDr. Bertaina is a highly experienced clinician and will play a key role in supporting Section Chief Dr. Rajni Agarwal and Clinical Staff in the Stem Cell Transplant Unit at Lucile Packard Children’s Hospital. She will also continue her research on immune recovery and miRNA, understanding the mechanisms underlying immune reconstitution, Graft-versus-Host Disease (GvHD), and leukemia relapse after allogeneic HSCT in pediatric patients affected by hematological malignant and non-malignant disorders.

  • Carolyn Bertozzi

    Carolyn Bertozzi

    Baker Family Director of Sarafan ChEM-H, Anne T. and Robert M. Bass Professor in the School of Humanities and Sciences and Professor, by courtesy, of Chemical and Systems Biology and of Radiology

    BioProfessor Carolyn Bertozzi's research interests span the disciplines of chemistry and biology with an emphasis on studies of cell surface sugars important to human health and disease. Her research group profiles changes in cell surface glycosylation associated with cancer, inflammation and bacterial infection, and uses this information to develop new diagnostic and therapeutic approaches, most recently in the area of immuno-oncology.

    Dr. Bertozzi completed her undergraduate degree in Chemistry at Harvard University and her Ph.D. at UC Berkeley, focusing on the chemical synthesis of oligosaccharide analogs. During postdoctoral work at UC San Francisco, she studied the activity of endothelial oligosaccharides in promoting cell adhesion at sites of inflammation. She joined the UC Berkeley faculty in 1996. A Howard Hughes Medical Institute Investigator since 2000, she came to Stanford University in June 2015, among the first faculty to join the interdisciplinary institute ChEM-H (Chemistry, Engineering & Medicine for Human Health). She is now the Baker Family Director of Stanford ChEM-H.

    Named a MacArthur Fellow in 1999, Dr. Bertozzi has received many awards for her dedication to chemistry, and to training a new generation of scientists fluent in both chemistry and biology. She has been elected to the Institute of Medicine, National Academy of Sciences, and American Academy of Arts and Sciences; and received the Lemelson-MIT Prize, the Heinrich Wieland Prize, the ACS Award in Pure Chemistry, and the Chemistry of the Future Solvay Prize, among others.

    The Bertozzi Group develops chemical tools to study the glycobiology underlying diseases such as cancer, inflammation, tuberculosis and most recently COVID-19. She is the inventor of "bioorthogonal chemistry", a class of chemical reactions compatible with living systems that enable molecular imaging and drug targeting. Her group also developed new therapeutic modalities for targeted degradation of extracellular biomolecules, such as antibody-enzyme conjugates and Lysosome Targeting Chimeras (LYTACs). As well, her group studies NGly1 deficiency, a rare genetic disease characterized by loss of the human N-glycanase.

    Several of the technologies developed in the Bertozzi lab have been adapted for commercial use. Actively engaged with several biotechnology start-ups, Dr. Bertozzi cofounded Redwood Bioscience, Enable Biosciences, Palleon Pharmaceuticals, InterVenn Bio, OliLux Bio, Grace Science LLC and Lycia Therapeutics. She is also a member of the Board of Directors of Lilly.

  • Allison Betof Warner, MD, PhD

    Allison Betof Warner, MD, PhD

    Assistant Professor of Medicine (Oncology)

    BioDr. Betof Warner is a board-certified, fellowship-trained medical oncologist with the Cutaneous Oncology Program and an Assistant Professor in the Department of Medicine, Division of Medical Oncology. She also serves as Director of Melanoma Medical Oncology, Director of Solid Tumor Cellular Therapy, and co-Director of the Pigmented Lesion and Melanoma Program.

    Clinical interests of Dr. Betof Warner include treatment of advanced melanoma, immunotherapy, and cellular therapies for solid tumors. She has been a pioneer in the use of commercial tumor infiltrating lymphocyte (TIL) therapy, which is expected to become standard of care for immunotherapy-refractory melanoma.

    Dr. Betof Warner serves as the leader of the Melanoma & Cutaneous Oncology Clinical Research Group, with research interests focused on tumor response to immunotherapy. She has been the principal investigator of multiple clinical trials focusing on immunotherapy-refractory melanoma and is internationally recognized for her expertise in central nervous system metastases and the use of novel cellular therapies. Dr. Betof Warner collaborates with investigators around the world in surgery, neuro-oncology, neurosurgery, radiation oncology, and pathology. She has received funding and awards for her clinical and translational investigative work from multiple high-profile organizations, including the American Society of Clinical Oncology (ASCO), National Institutes of Health (NIH), and Melanoma Research Foundation.

    In addition to publishing her research in peer-reviewed journals, Dr. Betof Warner has served as an editorial and grant reviewer for multiple organizations, including the Melanoma Research Foundation. She has authored book chapters and case reports, contributed to national guidelines, and presented her findings at regional, national, and international meetings.

    Dr. Betof Warner is a member of multiple professional organizations and societies, including the American Association for Cancer Research, the American Society of Clinical Oncology, and the Society for Immunotherapy of Cancer, where she serves on the Early Career Scientist Committee. She is also a member of the American College of Sports Medicine and the European Society for Medical Oncology.

  • Ami Bhatt

    Ami Bhatt

    Associate Professor of Medicine (Hematology) and of Genetics

    Current Research and Scholarly InterestsThe Bhatt lab is exploring how the microbiota is intertwined with states of health and disease. We apply the most modern genetic tools in an effort to deconvolute the mechanism of human diseases.

  • Michael S Binkley, MD, MS

    Michael S Binkley, MD, MS

    Assistant Professor of Radiation Oncology (Radiation Therapy)

    BioDr. Binkley is a radiation oncologist specializing in lymphoma treatment and an assistant professor in the Stanford University School of Medicine Department of Radiation Oncology.

    His clinical expertise includes stereotactic ablative radiotherapy (SABR), total lymphoid and total body irradiation, and intensity modulated radiation therapy (IMRT).

    For each patient, Dr. Binkley develops a personalized, comprehensive, and compassionate care plan. His goals are to improve both health and quality of life.

    Dr. Binkley has conducted extensive research to advance cancer treatment. In his post-doctoral fellowship at Stanford, he studied the use of genomic signatures to predict response to radiotherapy. His current clinical and laboratory research seek to identify prognostic and predictive clinical, radiographic, and genomic factors to inform individualized treatment strategies.

    He has co-authored articles on his research discoveries published in Cancer Discovery, Blood, the International Journal of Radiation Oncology*Biology*Physics, and elsewhere. Topics have included innovations in the treatment of lymphoma and lung cancer.

    He also has made invited presentations to colleagues at national and international conferences. He has presented the latest findings on radiation therapy for lung cancer and lymphoma at meetings of the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and International Conference on Malignant Lymphoma (ICML).

    Honors for Dr. Binkley include the Malcolm A. Bagshaw Award for leadership and outstanding scientific achievement. This award is named for a pioneer in radiation therapy and former chair of the Departments of Radiology and Radiation Oncology at Stanford University School of Medicine.

    Dr. Binkley is a member of the American Society of Clinical Oncology, American Society for Radiation Oncology, and American Association for Cancer Research. He is a founding member of the Global nLPHL One Working (GLOW) Working Group, an international collaboration studying nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) in children and adults.

  • Francis Blankenberg

    Francis Blankenberg

    Associate Professor of Radiology (Pediatric Radiology) and, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsStudies on apoptotic cell death in vivo using the H MRS phenomenon.

  • Helen M. Blau

    Helen M. Blau

    Donald E. and Delia B. Baxter Foundation Professor, Director, Baxter Laboratory for Stem Cell Biology and Professor, by courtesy, of Psychiatry and Behavioral Sciences

    Current Research and Scholarly InterestsProf. Helen Blau's research area is regenerative medicine with a focus on stem cells. Her research on nuclear reprogramming and demonstrating the plasticity of cell fate using cell fusion is well known and her laboratory has also pioneered the design of biomaterials to mimic the in vivo microenvironment and direct stem cell fate. Current findings are leading to more efficient iPS generation, cell based therapies by dedifferentiation a la newts, and discovery of novel molecules and therapies.

  • Douglas W. Blayney

    Douglas W. Blayney

    Professor of Medicine (Oncology), Emeritus

    Current Research and Scholarly InterestsImproving the quality of cancer care at Stanford, in our network of care, and nationally

  • Nikolas Blevins, MD

    Nikolas Blevins, MD

    Larry and Sharon Malcolmson Professor in the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery

    Current Research and Scholarly InterestsInner ear microendoscopy -- Developing techniques for minimally-invasive imaging of inner ear microanatomy and neural pysiology. Applications include improved cochlear implant development, inner ear regenerative techniques, inner ear surgery, and auditory physiology.

    Microsurgical robotics -- Developing scalable microsurgical instrumentation and robotic techniques for use in head and neck surgery.

    Surgical Simulation -- Immersive environment for temporal bone surgical simulation.

  • Daniel Bloch

    Daniel Bloch

    Professor (Research) of Biomedical Data Science (BDS), Emeritus

    BioI received my PhD. in Mathematical Statistics in 1967. I joined the research community at the Stanford University School of Medicine, Division of Immunology & Rheumatology, in 1984 as head statistician directing the biostatistics consulting and analytic support of the Arthritis Rheumatism Aging Medical Information System (ARAMIS) and Multipurpose Arthritis Center (MAC) grant-related research programs. In 1993 I was appointed Associate Professor with a joint appointment in the Departments of Medicine and of Health Research & Policy, and am currently Professor of Biostatistics at Stanford University, emeritus since 2007. My contributions to the statistics literature span numerous fields, including methods of sample size estimation, efficiency and bias of estimators, research methods for kappa statistics, non-parametric classification methods and methods of assessing multi-parameter endpoints. I have over 200 peer-reviewed publications. I have been directly involved with the development of numerous criteria rules for classification of diseases and with establishing guidelines for clinical trial research and in proposing responder criteria for osteoarthritis drugs. Since 1987, I have been a consultant on an ad hoc basis to pharmaceutical and biotechnical firms, including both start-up and established companies. I have extensive experience with devices, drugs and biologics and have participated in all aspects of applying statistics to implement investigational plans; e.g.: for protocol development, design of trials, database design. I’ve been a member of the FDA Statistical Advisors Panel, the statistical member on numerous data safety monitoring boards, and frequently represent companies at meetings with the FDA

  • Paul D. Blumenthal, MD, MPH

    Paul D. Blumenthal, MD, MPH

    Professor of Obstetrics and Gynecology (Gynecology-Family Planning) at the Stanford University Medical Center, Emeritus

    Current Research and Scholarly InterestsImproving Access to Family Planning Services in Low Resource Settings:

    Through a collaboration with Population Services International, the Stanford Program for International Reproductive Education and Services (SPIRES) provides technical direction in a program designed to improve access to and uptake of family planning, particularly Long Acting Reversible Contraception (LARC) such as IUDs and implants, in 14 developing countries globally. The first year saw insertion of over 280,000 IUDs.

  • Matthew Bogyo

    Matthew Bogyo

    Professor of Pathology and of Microbiology and Immunology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsOur lab uses chemical, biochemical, and cell biological methods to study protease function in human disease. Projects include:

    1) Design and synthesis of novel chemical probes for serine and cysteine hydrolases.

    2) Understanding the role of hydrolases in bacterial pathogenesis and the human parasites, Plasmodium falciparum and Toxoplasma gondii.

    3) Defining the specific functional roles of proteases during the process of tumorogenesis.

    4) In vivo imaging of protease activity

  • Sam Bollinger

    Sam Bollinger

    Ph.D. Student in Cancer Biology, admitted Autumn 2021

    BioOriginally from State College, Pennsylvania, Sam graduated with honors from Penn State University with a B.S. in Chemistry and a minor in Biology. He subsequently spent three years working at the Lankenau Institute for Medical Research for Dr. Ellen Heber-Katz. Sam hopes to expand the paradigm of cancer research and help to develop novel therapies for cancer and other ailments. He is also interested in optimization of physical and mental performance.

  • Melissa L Bondy

    Melissa L Bondy

    Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by courtesy, of Pediatrics

    Current Research and Scholarly InterestsPrincipal Investigator, Discovery, Biology and Risk of Inherited Variants in Glioma, 1R01CA217105-01A1, NIH/NCI, 05/01/2018-06/30/2022, MPI (Contact PI)

    Principal Investigator, Characterizing Germline and Somatic Alterations by Glioma Subtypes and Clinical Outcome, 1R01CA232754-01, 07/01/2019-06/30/2023, MPI (Contact PI)

    Co-Leader (Project), SPORE in Brain Cancer, PI – Fred Lang (Sub with MD Anderson), 2 P50CA127001-11, 09/01/2019-08/31/2023

    Co-Investigator, Stanford University Cancer Center, PI – Steve Artandi, P30 CA124435, NCI, 09/15/10-05/31/22

    Co-Investigator, Ovarian Cancer Survival in African-American Women, PI, Joellen Schildkraut, R01 CA237318-01A1, NIH/NCI, 07/01/2020-06/31/2025

  • Donna M. Bouley, DVM, PhD

    Donna M. Bouley, DVM, PhD

    Professor of Comparative Medicine at the Stanford University Medical Center, Emerita

    Current Research and Scholarly InterestsResearch interests: ocular pathology, host-pathogen interactions in infectious disease, infectious disease in frogs, phenotypic characterization of tg and ko mice, histopathology of minimally-invasive radiological ablation techniques (focused ultrasound, cryoablation).

  • Linda Boxer, MD, PhD

    Linda Boxer, MD, PhD

    Vice Dean of the School of Medicine and Stanley McCormick Memorial Professor

    Current Research and Scholarly InterestsRegulation of expression of oncogenes in normal and malignant hematologic cells.

  • Scott D. Boyd, MD PhD

    Scott D. Boyd, MD PhD

    Stanford Professor of Food Allergy and Immunology and Professor of Pathology

    Current Research and Scholarly InterestsOur goal is to understand the lymphocyte genotype-phenotype relationships in healthy human immunity and in immunological diseases. We apply new technologies and data analysis approaches to this challenge, particularly high-throughput DNA sequencing and single-cell monoclonal antibody generation, in parallel with other functional assays.

  • Onn Brandman

    Onn Brandman

    Associate Professor of Biochemistry and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsThe Brandman Lab studies how cells sense and respond to stress. We employ an integrated set of techniques including single cell analysis, mathematical modeling, genomics, structural studies, and in vitro assays.

  • James D. Brooks

    James D. Brooks

    Keith and Jan Hurlbut Professor

    Current Research and Scholarly InterestsWe use genomic approaches to identify disease biomarkers. We are most interested in translating biomarkers into clinical practice in urological diseases with a particular focus in cancer.

  • Martin Brown

    Martin Brown

    Professor of Radiation Oncology, Emeritus

    Current Research and Scholarly InterestsWe seek to understand the mechanisms responsible for the resistance of cancers to treatment and to develop strategies to overcome these resistances. We are using molecular and cellular techniques and mouse models to potentiate the activity of radiation on tumors by inhibiting the bone marrow rescue of the tumor vasculature following therapy.

  • Anne Brunet

    Anne Brunet

    Michele and Timothy Barakett Endowed Professor

    Current Research and Scholarly InterestsOur lab studies the molecular basis of longevity. We are interested in the mechanism of action of known longevity genes, including FOXO and SIRT, in the mammalian nervous system. We are particularly interested in the role of these longevity genes in neural stem cells. We are also discovering novel genes and processes involved in aging using two short-lived model systems, the invertebrate C. elegans and an extremely short-lived vertebrate, the African killifish N. furzeri.

  • Kelly Bugos MS, ANP-BC, NPD-BC, AOCNP

    Kelly Bugos MS, ANP-BC, NPD-BC, AOCNP

    Affiliate, Central Mgmt-Misc AR

    BioKelly Bugos MS, ANP-BC is a Director for the Center for Advanced Practice and a nurse practitioner specializing in cancer survivorship at Stanford Health Care. Ms. Bugos is the Director of Professional Development and the Advanced Practice Provider (APP) Fellowship Program. As director, Ms. Bugos focuses on APP leadership development. Opened in 2016, the APP Fellowship Program educates and trains APPs in transition to professional practice and specialty care, like administration and cancer care. She founded the cancer survivorship clinics at Stanford in 2012 and continues to focus her clinical work on helping people touched by cancer restore their health after treatment. Ms. Bugos has developed other professional roles and programs over her career at Stanford, like the nurse practitioner position in the 1990s. She has expertise in leadership of advanced practice providers, complex patient care in the outpatient setting, long term and late effects of cancer and its treatment, including symptom management. She is a frequent speaker and author on these topics at the regional and national level.

  • Nam Quoc Bui

    Nam Quoc Bui

    Clinical Assistant Professor, Medicine - Oncology

    BioDr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in Sarcoma. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data.

    His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies. He is involved in numerous sarcoma clinical trials, leading efforts to take new therapeutics from the lab to clinical practice. He also is involved in education at the Stanford University School of Medicine, serving as a lecturer and mentor to students and trainees. Dr. Bui is the founding Editor-in-Chief of the journal “Current Problems in Cancer: Case Reports”, an international, peer-reviewed journal that publishes groundbreaking cases that give insight into redefining concepts in cancer.

  • Eugene Butcher

    Eugene Butcher

    Klaus Bensch Professor of Pathology

    Current Research and Scholarly InterestsOur interests include:
    1) The physiology and function of lymphocyte homing in local and systemic immunity;
    2) Biochemical and genetic studies of molecules that direct leukocyte recruitment;
    3) Chemotactic mechanisms and receptors in vascular and immune biology;
    4) Vascular control of normal and pathologic inflammation and immunity;
    5) Systems biology of immune cell trafficking and programming in tumor immunity.

  • Mark Buyyounouski, MD, MS, FASTRO

    Mark Buyyounouski, MD, MS, FASTRO

    Professor of Radiation Oncology (Radiation Therapy)

    Current Research and Scholarly InterestsPatient-centered and artificial intelligence-augmented medical decision making